DUBLIN, Dec. 18, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/c9chws/discovery_stage) has announced the addition of the "Discovery Stage Partnering Terms and Agreements" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This report contains over 2,500 links to online copies of actual discovery stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2007.
In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.
Key Topics Covered:
2. Why do companies partner at discovery stage?
2.2. The role of discovery stage partnering
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.5. The future of discovery stage partnering deals
3. Discovery stage deal strategies and structure
3.2. At what stage do companies partner?
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.7. Multicomponent preclinical stage partnering agreements
4. Discovery stage partnering payment strategies
4.2. Discovery stage payment strategies
5. Trends in discovery stage deal making
5.2. Discovery stage partnering over the years
5.3. Big pharma discovery stage dealmaking activity
5.4. Big biotech discovery stage dealmaking activity
5.5. Discovery stage partnering by deal type
5.6. Discovery stage partnering by disease type
5.7. Partnering by discovery stage technology type
6. Average payment terms for discovery stage partnering
6.2. Guidelines for discovery stage payment terms
6.3. Discovery stage payment terms - deal data analysis
6.4. Payment terms analysis
7. Leading preclinical stage deals
7.2. Top discovery stage deals by value
8. Big pharma and big biotech discovery stage partnering deals
8.2. How to use big pharma/big biotech discovery stage partnering deals
8.3. Big pharma discovery stage partnering company profiles
8.4. Big biotech discovery stage partnering company profiles
9. Discovery stage partnering contracts directory
9.2. Company A-Z
9.3. By deal type
9.4. By stage of development
9.5. By therapy area
10. Discovery stage dealmaking directory
10.2. Deals by discovery stage
- Abbott Japan
- Boehringer Ingelheim
- Cypress Bioscience
- Dynavax Technologies
- Forest Pharmaceuticals
- Hyperion Therapeutics
- Ironwood Pharmaceuticals
- Janssen Research & Development
- KaloBios Pharmaceuticals
- La Jolla Pharmaceutical
- Mylan Laboratories
- Novo Nordisk
- Ortho Biotech
- Regeneron Pharmaceuticals
- Sucampo Pharmaceuticals
- Transcept Pharmaceuticals
- Victory Pharma
- Warner Chilcott
For more information visit http://www.researchandmarkets.com/research/c9chws/discovery_stage
Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets